Ameliorative Effect of Glycyrrhizic Acid on Diosbulbin B-Induced Liver Injury and Its Mechanism

This study aimed to clarify the protective effect of Glycyrrhizic acid (GL) against Diosbulbin B (DB) - induced liver injury in mice and investigate its mechanisms of action. A liver injury DB was established in mice through the oral administration of DB for 15 days. At the same time, GL was adminis...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of Chinese medicine (1979) Vol. 53; no. 1; p. 309
Main Authors: Wang, Xin, Shi, Lei-Lei, Zhang, Yu-Han, Zhu, Hong-Zhe, Cao, Shan-Shan, Shi, Yong, Shangguan, Hui-Zi, Liu, Ji-Ping, Xie, Yun-Dong
Format: Journal Article
Language:English
Published: Singapore 2025
Subjects:
ISSN:1793-6853, 1793-6853
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract This study aimed to clarify the protective effect of Glycyrrhizic acid (GL) against Diosbulbin B (DB) - induced liver injury in mice and investigate its mechanisms of action. A liver injury DB was established in mice through the oral administration of DB for 15 days. At the same time, GL was administered to the mice for treatment. After the experiment, the pharmacodynamics and mechanisms of GL in ameliorating DB-induced liver injury were explored using biochemical indexes, non-targeted metabolomics, targeted metabolomics, Western blotting analysis of protein expression, 16S rDNA sequencing, and Spearman correlation analysis. The results show reduced liver function indices and improved DB-induced hepatic pathological changes. It also attenuated DB-induced hepatic inflammation and oxidative stress. Hepatic metabolomics revealed that GL regulated ABC transporters and bile secretion. Targeted bile acid (BA) metabolomics and Western blotting demonstrated that GL improved DB-induced reduction in BA efflux by regulating FXR-mediated efflux transporters. Furthermore, analysis of 16S rDNA gene sequencing revealed that GL effectively restored the relative abundance of beneficial bacteria, reduced the relative abundance of harmful bacteria, and reinstated the structure of the intestinal flora. Additionally, correlation analyses between BA and intestinal flora indicated that , TDGA, DGA, UDGA, GDGA, THDGA, and HDGA could serve as major markers for DB-induced liver injury. In conclusion, GL significantly improved DB-induced liver injury by increasing the expression of Nrf2/FXR-BSEP/MRP2/P-gp/UGT1A1, promoting BA efflux, regulating intestinal flora, and alleviating inflammation and oxidative stress.
AbstractList This study aimed to clarify the protective effect of Glycyrrhizic acid (GL) against Diosbulbin B (DB) - induced liver injury in mice and investigate its mechanisms of action. A liver injury DB was established in mice through the oral administration of DB for 15 days. At the same time, GL was administered to the mice for treatment. After the experiment, the pharmacodynamics and mechanisms of GL in ameliorating DB-induced liver injury were explored using biochemical indexes, non-targeted metabolomics, targeted metabolomics, Western blotting analysis of protein expression, 16S rDNA sequencing, and Spearman correlation analysis. The results show reduced liver function indices and improved DB-induced hepatic pathological changes. It also attenuated DB-induced hepatic inflammation and oxidative stress. Hepatic metabolomics revealed that GL regulated ABC transporters and bile secretion. Targeted bile acid (BA) metabolomics and Western blotting demonstrated that GL improved DB-induced reduction in BA efflux by regulating FXR-mediated efflux transporters. Furthermore, analysis of 16S rDNA gene sequencing revealed that GL effectively restored the relative abundance of beneficial bacteria, reduced the relative abundance of harmful bacteria, and reinstated the structure of the intestinal flora. Additionally, correlation analyses between BA and intestinal flora indicated that Firmicutes, Bacteroidota, TDGA, DGA, UDGA, GDGA, THDGA, and HDGA could serve as major markers for DB-induced liver injury. In conclusion, GL significantly improved DB-induced liver injury by increasing the expression of Nrf2/FXR-BSEP/MRP2/P-gp/UGT1A1, promoting BA efflux, regulating intestinal flora, and alleviating inflammation and oxidative stress.This study aimed to clarify the protective effect of Glycyrrhizic acid (GL) against Diosbulbin B (DB) - induced liver injury in mice and investigate its mechanisms of action. A liver injury DB was established in mice through the oral administration of DB for 15 days. At the same time, GL was administered to the mice for treatment. After the experiment, the pharmacodynamics and mechanisms of GL in ameliorating DB-induced liver injury were explored using biochemical indexes, non-targeted metabolomics, targeted metabolomics, Western blotting analysis of protein expression, 16S rDNA sequencing, and Spearman correlation analysis. The results show reduced liver function indices and improved DB-induced hepatic pathological changes. It also attenuated DB-induced hepatic inflammation and oxidative stress. Hepatic metabolomics revealed that GL regulated ABC transporters and bile secretion. Targeted bile acid (BA) metabolomics and Western blotting demonstrated that GL improved DB-induced reduction in BA efflux by regulating FXR-mediated efflux transporters. Furthermore, analysis of 16S rDNA gene sequencing revealed that GL effectively restored the relative abundance of beneficial bacteria, reduced the relative abundance of harmful bacteria, and reinstated the structure of the intestinal flora. Additionally, correlation analyses between BA and intestinal flora indicated that Firmicutes, Bacteroidota, TDGA, DGA, UDGA, GDGA, THDGA, and HDGA could serve as major markers for DB-induced liver injury. In conclusion, GL significantly improved DB-induced liver injury by increasing the expression of Nrf2/FXR-BSEP/MRP2/P-gp/UGT1A1, promoting BA efflux, regulating intestinal flora, and alleviating inflammation and oxidative stress.
This study aimed to clarify the protective effect of Glycyrrhizic acid (GL) against Diosbulbin B (DB) - induced liver injury in mice and investigate its mechanisms of action. A liver injury DB was established in mice through the oral administration of DB for 15 days. At the same time, GL was administered to the mice for treatment. After the experiment, the pharmacodynamics and mechanisms of GL in ameliorating DB-induced liver injury were explored using biochemical indexes, non-targeted metabolomics, targeted metabolomics, Western blotting analysis of protein expression, 16S rDNA sequencing, and Spearman correlation analysis. The results show reduced liver function indices and improved DB-induced hepatic pathological changes. It also attenuated DB-induced hepatic inflammation and oxidative stress. Hepatic metabolomics revealed that GL regulated ABC transporters and bile secretion. Targeted bile acid (BA) metabolomics and Western blotting demonstrated that GL improved DB-induced reduction in BA efflux by regulating FXR-mediated efflux transporters. Furthermore, analysis of 16S rDNA gene sequencing revealed that GL effectively restored the relative abundance of beneficial bacteria, reduced the relative abundance of harmful bacteria, and reinstated the structure of the intestinal flora. Additionally, correlation analyses between BA and intestinal flora indicated that , TDGA, DGA, UDGA, GDGA, THDGA, and HDGA could serve as major markers for DB-induced liver injury. In conclusion, GL significantly improved DB-induced liver injury by increasing the expression of Nrf2/FXR-BSEP/MRP2/P-gp/UGT1A1, promoting BA efflux, regulating intestinal flora, and alleviating inflammation and oxidative stress.
Author Shi, Lei-Lei
Shangguan, Hui-Zi
Wang, Xin
Xie, Yun-Dong
Zhu, Hong-Zhe
Cao, Shan-Shan
Liu, Ji-Ping
Shi, Yong
Zhang, Yu-Han
Author_xml – sequence: 1
  givenname: Xin
  orcidid: 0009-0003-3365-1141
  surname: Wang
  fullname: Wang, Xin
  organization: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1, Middle Section of Century Avenue, Xianyang 712046, P. R. China
– sequence: 2
  givenname: Lei-Lei
  orcidid: 0009-0003-5902-7232
  surname: Shi
  fullname: Shi, Lei-Lei
  organization: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1, Middle Section of Century Avenue, Xianyang 712046, P. R. China
– sequence: 3
  givenname: Yu-Han
  orcidid: 0009-0004-3551-6178
  surname: Zhang
  fullname: Zhang, Yu-Han
  organization: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1, Middle Section of Century Avenue, Xianyang 712046, P. R. China
– sequence: 4
  givenname: Hong-Zhe
  orcidid: 0009-0003-0709-2454
  surname: Zhu
  fullname: Zhu, Hong-Zhe
  organization: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1, Middle Section of Century Avenue, Xianyang 712046, P. R. China
– sequence: 5
  givenname: Shan-Shan
  orcidid: 0009-0003-4608-7498
  surname: Cao
  fullname: Cao, Shan-Shan
  organization: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1, Middle Section of Century Avenue, Xianyang 712046, P. R. China
– sequence: 6
  givenname: Yong
  orcidid: 0009-0004-3928-743X
  surname: Shi
  fullname: Shi, Yong
  organization: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1, Middle Section of Century Avenue, Xianyang 712046, P. R. China
– sequence: 7
  givenname: Hui-Zi
  orcidid: 0009-0001-5940-2392
  surname: Shangguan
  fullname: Shangguan, Hui-Zi
  organization: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1, Middle Section of Century Avenue, Xianyang 712046, P. R. China
– sequence: 8
  givenname: Ji-Ping
  orcidid: 0000-0001-8138-9561
  surname: Liu
  fullname: Liu, Ji-Ping
  organization: Shaanxi Key Laboratory for Safety Monitoring of Food and Drug, Xianyang 712046, P. R. China
– sequence: 9
  givenname: Yun-Dong
  orcidid: 0009-0008-9358-4864
  surname: Xie
  fullname: Xie, Yun-Dong
  organization: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1, Middle Section of Century Avenue, Xianyang 712046, P. R. China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39829229$$D View this record in MEDLINE/PubMed
BookMark eNpNUM1LwzAcDTJxH_oHeJEcvVSbpFnS49Q5CxMPKngrSfoLy2jTmbRC_estOMHTe_A-4L05mvjWA0KXJL0hJKO3rynJaUb4B-U8TQlNT9CMiJwlS8nZ5B-fonmM-9HChFyeoSnLJc0pzWeoXDVQuzaozn0BXlsLpsOtxZt6MEMIO_ftDF4ZV-HW4wfXRt3X2nl8lxS-6g1UeDsGAy78vg8DVr7CRRfxM5id8i425-jUqjrCxREX6P1x_Xb_lGxfNsX9apsYRrIuMUvOQUmriRWaKhCaZFKnAnTOLXDG2YgagOhKSCsYlVJRgGWeGZuNCl2g69_eQ2g_e4hd2bhooK6Vh7aPJSNcjCdl4_AFujpae91AVR6Ca1QYyr9T6A872maN
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1142/S0192415X25500120
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1793-6853
ExternalDocumentID 39829229
Genre Journal Article
GroupedDBID ---
.GJ
0R~
123
23M
36B
4.4
53G
5RE
6J9
6NX
6PF
AAWTL
ADSJI
AEGXH
AENEX
AFOSN
AIZAD
ALMA_UNASSIGNED_HOLDINGS
C1A
CAG
CGR
COF
CS3
CUY
CVF
EBS
ECM
ECV
EIF
EJD
EMOBN
F5P
FAL
FEDTE
FJD
FJW
HVGLF
HZ~
NPM
O9-
P2P
P71
PQQKQ
RWJ
WH7
WQ9
WSL
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c314t-c655ea8fb1f7b2ae7b148b07eb95fe535395fbee1bd78f73288a2ee694cf45fb2
IEDL.DBID 7X8
ISICitedReferencesCount 3
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001399109900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1793-6853
IngestDate Thu Oct 02 05:40:46 EDT 2025
Sat May 03 02:01:26 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Diosbulbin B
Bile Acid
Glycyrrhizic Acid
Hepatotoxicity
Intestinal Flora
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c314t-c655ea8fb1f7b2ae7b148b07eb95fe535395fbee1bd78f73288a2ee694cf45fb2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0009-0003-4608-7498
0009-0001-5940-2392
0000-0001-8138-9561
0009-0003-3365-1141
0009-0004-3551-6178
0009-0004-3928-743X
0009-0008-9358-4864
0009-0003-5902-7232
0009-0003-0709-2454
PMID 39829229
PQID 3157550498
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3157550498
pubmed_primary_39829229
PublicationCentury 2000
PublicationDate 2025-00-00
20250101
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – year: 2025
  text: 2025-00-00
PublicationDecade 2020
PublicationPlace Singapore
PublicationPlace_xml – name: Singapore
PublicationTitle The American journal of Chinese medicine (1979)
PublicationTitleAlternate Am J Chin Med
PublicationYear 2025
SSID ssj0013786
Score 2.3974392
Snippet This study aimed to clarify the protective effect of Glycyrrhizic acid (GL) against Diosbulbin B (DB) - induced liver injury in mice and investigate its...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 309
SubjectTerms Animals
ATP-Binding Cassette Transporters - metabolism
Bile Acids and Salts - metabolism
Chemical and Drug Induced Liver Injury - drug therapy
Chemical and Drug Induced Liver Injury - etiology
Chemical and Drug Induced Liver Injury - metabolism
Disease Models, Animal
Gastrointestinal Microbiome - drug effects
Glycyrrhizic Acid - administration & dosage
Glycyrrhizic Acid - pharmacology
Glycyrrhizic Acid - therapeutic use
Heterocyclic Compounds, 4 or More Rings - adverse effects
Liver - drug effects
Liver - metabolism
Liver - pathology
Male
Mice
Oxidative Stress - drug effects
Title Ameliorative Effect of Glycyrrhizic Acid on Diosbulbin B-Induced Liver Injury and Its Mechanism
URI https://www.ncbi.nlm.nih.gov/pubmed/39829229
https://www.proquest.com/docview/3157550498
Volume 53
WOSCitedRecordID wos001399109900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC61Gw2r5PUd8EWQYXewu5mFiNtUptWqL_e2SRFL4LgJTmEQJiZzHzz2G8IOcOgBeD7hkntBUz4QjKpTMQwuAOag0bHWfLMPgS9XtjvR491wa2oxyrnPrF01EmubY285ToILDzEs-HF6J3ZrVG2u1qv0FgkDRehjB3pCvo_ughBuenR2iDzMS7VXU1H8NaThTYYvPoIqcsDpL8jzDLS3K7_9xs3yFqNMWm7MopNsgDZFlnp1l30bRK3hzBI84rzm1b8xTQ39G4w07Px-DX9TDVt6zSheUav07xQ0wEm0PSS2UUfGhL6YKc5aCd7Q41QmSW0MyloF-wp4rQY7pCX25vnq3tWL1pg2nXEhGnf80CGRjkmUFxCoDBJUucBqMgz4Lmei3cF4KgkCI2l9wklRxVHQhuBT_guWcryDPYJTbQQlhHHTyASKuFSQYgZpvK1g1BRRk1yOhddjIZsuxMyg3xaxN_Ca5K9Sv7xqGLciFG1POI8OvjD24dkldsdvWWZ5Ig0DP7GcEyW9cckLcYnpYXgtffY_QKQl8V0
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ameliorative+Effect+of+Glycyrrhizic+Acid+on+Diosbulbin+B-Induced+Liver+Injury+and+Its+Mechanism&rft.jtitle=The+American+journal+of+Chinese+medicine+%281979%29&rft.au=Wang%2C+Xin&rft.au=Shi%2C+Lei-Lei&rft.au=Zhang%2C+Yu-Han&rft.au=Zhu%2C+Hong-Zhe&rft.date=2025-01-01&rft.issn=1793-6853&rft.eissn=1793-6853&rft.volume=53&rft.issue=1&rft.spage=309&rft_id=info:doi/10.1142%2FS0192415X25500120&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1793-6853&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1793-6853&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1793-6853&client=summon